Anterogen.Co.,Ltd. (KOSDAQ:065660)

Anterogen.Co.,Ltd. Revenue

Anterogen.Co.,Ltd. had revenue of 2.20B KRW in the quarter ending June 30, 2026, with 16.53% growth. This brings the company's total for the last twelve months to 8.37B, up 16.55% year-over-year. In the year 2025, Anterogen.Co.,Ltd. had annual revenue of 7.54B with 8.71% growth. That makes Anterogen.Co.,Ltd. the 39,228th largest company in the world by revenue and 2,460th in South Korea.

• Revenue (ttm): 8.37B
• Revenue Growth: +16.55%
• P/S Ratio: 15.97
• Revenue / Employee: n/a
• Employees: n/a
• Market Cap: 135.68B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

• Cell Therapy Products and Rare Drugs Merchandise 5.36B 82.4%
• Cell Therapy Products and Rare Drugs Product 1.14B 17.6%
• Other 1.95M 0.0%

By Geography

• South Korea 6.03B 92.7%
• Overseas 471.60M 7.3%

Fiscal year ended Dec 31, 2023 See the full Anterogen.Co.,Ltd. breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	7.54B	603.60M	8.71%
Dec 31, 2024	6.93B	432.62M	6.66%
Dec 31, 2023	6.50B	-90.76M	-1.38%
Dec 31, 2022	6.59B	-1.53B	-18.85%
Dec 31, 2021	8.12B	3.97B	95.64%

Data Source: S&P Global Market Intelligence Last updated: Jul 30, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 28, 2026

Data Sources Report a data error